Tuoji Pharmaceuticals has completed a $40 million Series A financing round, jointly led by Oriza Seed and Decheng Capital, with participation from Longpan Investment, Jifeng Capital, Mifen Health Fund, Songqing Capital, and Xiamen Jianfa.
According to public information, Tuoji Pharmaceuticals was established in early 2022. Its founder, Dr. Chen Zhaoyuan, is a senior scientist in the ADC field who has led the research and development of more than 10 ADC drug pipelines. The company focuses on bispecific antibody-drug conjugates (BsAb-ADC) and dual-payload ADCs, and has built a technology platform covering antibody discovery, Linker-Payload design, site-specific conjugation, and functional evaluation.
Its core product TJ101, a bispecific ADC targeting EGFR/B7-H3, is currently conducting clinical enrollment in both China and the United States.
Comments